Compare WSO & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | CYTK |
|---|---|---|
| Founded | 1945 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 10.7B |
| IPO Year | 1994 | 2004 |
| Metric | WSO | CYTK |
|---|---|---|
| Price | $303.65 | $54.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 14 | 22 |
| Target Price | ★ $347.70 | $107.39 |
| AVG Volume (30 Days) | 686.0K | ★ 1.5M |
| Earning Date | 10-27-2026 | 11-04-2026 |
| Dividend Yield | ★ 4.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.92 | N/A |
| Revenue | ★ $7,239,290,000.00 | $13,368,000.00 |
| Revenue This Year | $5.93 | $79.67 |
| Revenue Next Year | $10.21 | $172.23 |
| P/E Ratio | $54.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $277.34 | $58.43 |
| 52 Week High | $459.00 | $88.31 |
| Indicator | WSO | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 29.20 |
| Support Level | $301.43 | N/A |
| Resistance Level | $324.73 | $66.93 |
| Average True Range (ATR) | 14.70 | 2.39 |
| MACD | 1.06 | -0.35 |
| Stochastic Oscillator | 45.06 | 4.21 |
Watsco is the largest HVAC and refrigeration products distributor in North America with approximately 13% market share. The company primarily operates in the United States (90% of revenue) with significant exposure in the Sunbelt states. Watsco also has operations in Canada, Latin America, and the Caribbean. The company's customer base comprises more than 120,000 dealers and contractors serving the replacement and new-construction HVAC/R markets for residential and light-commercial applications. As much as 20% of residential HVAC units are distributed through Watsco in any given year. Revenue is approximately 75%-80% residential HVAC and 20%-25% commercial, with relatively small exposure to more complex "applied" solutions.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.